A Search Service for Abbreviation / Long Form

■ Related PubMed/MEDLINE Info.

[Related PubMed/MEDLINE]
Total Number of Papers: 325
[Display Entries]
100 entries :
      (Publication year, Descending)
100 entries :
      (Publication year, Ascending)
all entries
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation : OvCa
Long Form : ovarian cancer
No. Year Title Co-occurring Abbreviation
2022 A blood-based metabolite panel for distinguishing ovarian cancer from benign pelvic masses. BPM, ROMA
2022 Abnormal spindle-like microcephaly-associated protein promotes proliferation by regulating cell cycle in epithelial ovarian cancer. ASPM, EdU, EOC, IHC, KEGG, siRNA, TMA
2022 Another Wrinkle with Age: Aged Collagen and Intra-peritoneal Metastasis of Ovarian Cancer. CAFs, CHP, i.p, SEM, SHG
2022 Compound C Inhibits Ovarian Cancer Progression via PI3K-AKT-mTOR-NFκB Pathway. HGSC, TME
2022 CRISPR-mediated TGFBR2 knockout renders human ovarian cancer tumor-infiltrating lymphocytes resistant to TGF-β signaling. TGFBR2, TIL
2022 CRMP2 derived from cancer associated fibroblasts facilitates progression of ovarian cancer via HIF-1α-glycolysis signaling pathway. CAFs, CRMP2, EOC, HIF, MS, r-CRMP2, TME
2022 Cryptocaryone Promotes ROS-Dependent Antiproliferation and Apoptosis in Ovarian Cancer Cells. CPC
2022 Design, Synthesis, and Preclinical Activity in Ovarian Cancer Models of New Phosphanegold(I)-N-heterocyclic Carbene Complexes. ---
2022 DHMEQ enhances the cytotoxic effect of cisplatin and carboplatin in ovarian cancer cell lines. CBP
10  2022 Differential Expression of RAD51AP1 in Ovarian Cancer: Effects of siRNA In Vitro. DEGs, RAD51AP1, T2DM
11  2022 Differential Regulation of Genes by the Glucogenic Hormone Asprosin in Ovarian Cancer. ---
12  2022 Effective Combination Immunotherapy with Oncolytic Adenovirus and Anti-PD-1 for Treatment of Human and Murine Ovarian Cancers. ICI
13  2022 Exosomal miR-543 Inhibits the Proliferation of Ovarian Cancer by Targeting IGF2. IGF2, miR-543
14  2022 Exosomal Plasma Gelsolin Is an Immunosuppressive Mediator in the Ovarian Tumor Microenvironment and a Determinant of Chemoresistance. GSN, pGSN, pGSN
15  2022 Exploring Resource-Sharing Behaviors for Finding Relevant Health Resources: Analysis of an Online Ovarian Cancer Community. OHCs
16  2022 Identification of a Gene Signature of Cancer-Associated Fibroblasts to Predict Prognosis in Ovarian Cancer. CAFRS, CAFs, LASSO, WGCNA
17  2022 Identification of miR-30c-5p as a tumor suppressor by targeting the m6 A reader HNRNPA2B1 in ovarian cancer. miRNAs, PPI
18  2022 Integrated Microfluidic System for Cell-Free DNA Extraction from Plasma for Mutant Gene Detection and Quantification. cfDNA, IMC, qPCR
19  2022 Isolation and Quantification of Methylated Cell-Free DNA in Plasma on an Integrated Microfluidic System. cfDNA, qPCR
20  2022 Knowledge Acquisition and Social Support in Online Health Communities: Analysis of an Online Ovarian Cancer Community. OHCs
21  2022 MicroRNA-20a-5p inhibits the autophagy and cisplatin resistance in ovarian cancer via regulating DNMT3B-mediated DNA methylation of RBP1. qRT-PCR
22  2022 MicroRNA-506-3p inhibits ovarian cancer metastasis by down-regulating the expression of EZH2. ---
23  2022 Molecular Regulation of Androgen Receptors in Major Female Reproductive System Cancers. ARs, CC, EC
24  2022 Novel LncRNA ZFHX4-AS1 as a Potential Prognostic Biomarker That Affects the Immune Microenvironment in Ovarian Cancer. CCK, GO, GSEA, KEGG
25  2022 Ovarian Cancer: Applications of Chickens to Humans. TVUS
26  2022 Ovarian Cancers with Low CIP2A Tumor Expression Constitute an APR-246-Sensitive Disease Subtype. ---
27  2022 p53-driven replication stress in nucleoli of malignant epithelial ovarian cancer. CHK1-pS345, DDR
28  2022 Peritoneal restoration by repurposing vitamin D inhibits ovarian cancer dissemination via blockade of the TGF-β1/thrombospondin-1 axis. CAMs, MCs
29  2022 Placental Leucine Aminopeptidase as a Potential Specific Urine Biomarker for Invasive Ovarian Cancer. P-LAP
30  2022 Plasma Gelsolin Confers Chemoresistance in Ovarian Cancer by Resetting the Relative Abundance and Function of Macrophage Subtypes. ICBs, pGSN
31  2022 Pyroptosis: A Developing Foreland of Ovarian Cancer Treatment. ---
32  2022 SCD1/FADS2 fatty acid desaturases equipoise lipid metabolic activity and redox-driven ferroptosis in ascites-derived ovarian cancer cells. CSC, EOC, OCM, SCD1, UFAs
33  2022 Silencing of FANCI Promotes DNA Damage and Sensitizes Ovarian Cancer Cells to Carboplatin. BMF, CNVs, FA, HR, ICL
34  2022 The Proteolytic Landscape of Ovarian Cancer: Applications in Nanomedicine. ---
35  2022 Therapeutic targeting of DNA damage repair pathways guided by homologous recombination deficiency scoring in ovarian cancers. HRD
36  2022 Tissue-Specific Expression of TIGIT, PD-1, TIM-3, and CD39 by γδ T Cells in Ovarian Cancer. EM, TEMRA
37  2022 Tumor-associated macrophages induced spheroid formation by CCL18-ZEB1-M-CSF feedback loop to promote transcoelomic metastasis of ovarian cancer. M-CSF, ZEB1
38  2022 Understanding the Correlation between Metabolic Regulator SIRT1 and Exosomes with CA-125 in Ovarian Cancer: A Clinicopathological Study. BMI, OS
39  2022 Upregulation of CXCL1 and LY9 contributes to BRCAness in ovarian cancer and mediates response to PARPi and immune checkpoint blockade. HRD
40  2022 Wnt5A and TGFβ1 Converges through YAP1 Activity and Integrin Alpha v Up-Regulation Promoting Epithelial to Mesenchymal Transition in Ovarian Cancer Cells and Mesothelial Cell Activation. EMT, VP
41  2021 A large-scale multi-institutional study evaluating prognostic aspects of positive ascites cytology and effects of therapeutic interventions in epithelial ovarian cancer. ---
42  2021 A MYC-Driven Plasma Polyamine Signature for Early Detection of Ovarian Cancer. AUC, TNBC
43  2021 ADAM17 Inhibition Increases the Impact of Cisplatin Treatment in Ovarian Cancer Spheroids. ADAM17
44  2021 An aptamer interacting with heat shock protein 70 shows therapeutic effects and prognostic ability in serous ovarian cancer. CTCs, NK
45  2021 Analogs of a Natural Peptaibol Exert Anticancer Activity in Both Cisplatin- and Doxorubicin-Resistant Cells and in Multicellular Tumor Spheroids. HL
46  2021 Analysis of ovarian cancer cell secretome during epithelial to mesenchymal transition reveals a protein signature associated with advanced stages of ovarian tumors. EGF, EMT, HGSC, SILAC
47  2021 Androgen/Androgen Receptor Signaling in Ovarian Cancer: Molecular Regulation and Therapeutic Potentials. AR, CSPCs
48  2021 Characterization of ovarian cancer-derived extracellular vesicles by surface-enhanced Raman spectroscopy. EVs, hIOSE, SERS
49  2021 CircHIPK2 Contributes to DDP Resistance and Malignant Behaviors of DDP-Resistant Ovarian Cancer Cells Both in vitro and in vivo Through circHIPK2/miR-338-3p/CHTOP ceRNA Pathway. Bax, Bcl, CHTOP, circHIPK2, miR, MMP-2
50  2021 Clinical Implication of Metformin in Relation to Diabetes Mellitus and Ovarian Cancer. ---
51  2021 Confocal Imaging of Single-Cell Signaling in Orthotopic Models of Ovarian Cancer. MAPK, PI3K
52  2021 Credentialing and Pharmacologically Targeting PTP4A3 Phosphatase as a Molecular Target for Ovarian Cancer. ---
53  2021 DIAPH1 facilitates paclitaxel-mediated cytotoxicity of ovarian cancer cells. DIAPH1, PTX
54  2021 Dual inhibition of FGFR4 and BCL-xL inhibits multi-resistant ovarian cancer with BCL2L1 gain. CN, TMA
55  2021 Exploring the clinical value of tumor microenvironment in platinum-resistant ovarian cancer. ECM, HGSC, MDSCs, TME
56  2021 Ezrin Promotes the Proliferation, Migration, and Invasion of Ovarian Cancer Cells. EMT
57  2021 Feasibility and Assessment of a Cascade Traceback Screening Program (FACTS): Protocol for a Multisite Study to Implement and Assess an Ovarian Cancer Traceback Cascade Testing Program. FACTS
58  2021 Ferroptosis in Ovarian Cancer: A Novel Therapeutic Strategy. PARP
59  2021 Germline mutations in apoptosis pathway genes in ovarian cancer; the functional role of a TP53I3 (PIG3) variant in ROS production and DNA repair. VUS
60  2021 Host Mesothelin Expression Increases Ovarian Cancer Metastasis in the Peritoneal Microenvironment. MCAs, MSLN
61  2021 Identifying Language Features Associated With Needs of Ovarian Cancer Patients and Caregivers Using Social Media. OHCs
62  2021 Impact of incomplete surgery and adjuvant chemotherapy for the intraoperative rupture of capsulated stage I epithelial ovarian cancer: a multi-institutional study with an in-depth subgroup analysis. CI, HR, PS
63  2021 In Ovarian Cancer Multicellular Spheroids, Platelet Releasate Promotes Growth, Expansion of ALDH+ and CD133+ Cancer Stem Cells, and Protection against the Cytotoxic Effects of Cisplatin, Carboplatin and Paclitaxel. ALDH, CSCs, MCTS
64  2021 In Vivo and Ex Vivo Analysis of Omental Adhesion in Ovarian Cancer. ---
65  2021 Incidence of malignant transformation in the oviductal fimbria in laying hens, a preclinical model of spontaneous ovarian cancer. HGSC, TVUS
66  2021 Isolation and quantification of extracellular vesicle-encapsulated microRNA on an integrated microfluidic platform. EVs, LOD, miRNA-21
67  2021 Long-term post-recurrence survival outcomes in young women receiving fertility-sparing surgery for epithelial ovarian cancer. FSS
68  2021 Mesothelial-to-Mesenchymal Transition and Exosomes in Peritoneal Metastasis of Ovarian Cancer. CAFs, MMT, PMC
69  2021 Modeling the Tumor Microenvironment of Ovarian Cancer: The Application of Self-Assembling Biomaterials. TME
70  2021 Modified intestinal isolation bag as promising tool in promoting bowel resumption after ovarian cancer cytoreductive surgery: a randomized clinical trial. POI
71  2021 Nano-Based Drug Delivery and Targeting to Overcome Drug Resistance of Ovarian Cancers. MDR
72  2021 Newly developed dual topoisomerase inhibitor P8-D6 is highly active in ovarian cancer. SEM
73  2021 ONC201 induces the unfolded protein response (UPR) in high- and low-grade ovarian carcinoma cell lines and leads to cell death regardless of platinum sensitivity. HG, LG, UPR
74  2021 Ovarian Cancer-Associated Mesothelial Cells: Transdifferentiation to Minions of Cancer and Orchestrate Developing Peritoneal Dissemination. MCs, OCAMs
75  2021 PHLDA1 Modulates the Endoplasmic Reticulum Stress Response and is required for Resistance to Oxidative Stress-induced Cell Death in Human Ovarian Cancer Cells. PHLDA1, RT-qPCR
76  2021 Predicting master transcription factors from pan-cancer expression data. ---
77  2021 Pro-tumoral behavior of omental adipocyte-derived fibroblasts in tumor microenvironment at the metastatic site of ovarian cancer. O-ADF
78  2021 RANKL Blockade Reduces Cachexia and Bone Loss Induced by Non-Metastatic Ovarian Cancer in Mice. ASBMR, RANKL
79  2021 Silencing of let-7b-5p inhibits ovarian cancer cell proliferation and stemness characteristics by Asp-Glu-Ala-Asp-box helicase 19A. MB, miRNA
80  2021 Targeting autocrine amphiregulin robustly and reproducibly inhibits ovarian cancer in a syngeneic model: roles for wildtype p53. AREG, EGFR
81  2021 Utilizing digital pathology to quantify stromal caveolin-1 expression in malignant and benign ovarian tumors: Associations with clinicopathological parameters and clinical outcomes. CAF, Cav-1, IF, IHC
82  2020 A frequent somatic mutation in the 3'UTR of GAPDH facilitates the development of ovarian cancer by creating a miR‑125b binding site. UTR
83  2020 A PTAL-miR-101-FN1 Axis Promotes EMT and Invasion-Metastasis in Serous Ovarian Cancer. FN1, lncRNAs, PTAL
84  2020 Adipose-Derived Stem Cells Primed with Paclitaxel Inhibit Ovarian Cancer Spheroid Growth and Overcome Paclitaxel Resistance. ADSCs, CM, PTX, PTX
85  2020 Age-related copy number variations and expression levels of F-box protein FBXL20 predict ovarian cancer prognosis. CNVs, FBXL20
86  2020 Anti-proliferative activities of Byrsocarpus coccineus Schum. and Thonn. (Connaraceae) using ovarian cancer cell lines. ---
87  2020 Antitumor effects of aconitine in A2780cells via estrogen receptor beta‑mediated apoptosis, DNA damage and migration. ERbeta, MMP-2
88  2020 Ascites-induced compression alters the peritoneal microenvironment and promotes metastatic success in ovarian cancer. IPP, TNT
89  2020 Association between DNA damage repair gene somatic mutations and immune-related gene expression in ovarian cancer. DDR, NGS, TMB
90  2020 Cell type-specific genotoxicity in estrogen-exposed ovarian and fallopian epithelium. HR
91  2020 Characterization of BRCA1/2-Directed ceRNA Network Identifies a Novel Three-lncRNA Signature to Predict Prognosis and Chemo-Response in Ovarian Cancer Patients With Wild-Type BRCA1/2. BRCALncSig, CR, HR, lncRNAs
92  2020 Combining PARP with ATR inhibition overcomes PARP inhibitor and platinum resistance in ovarian cancer models. ATRi, PARPi, PDXs
93  2020 Comprehensive analysis of mRNA-level and miRNA-level subpathway activities for identifying robust ovarian cancer prognostic signatures. ---
94  2020 Computational-based identification and analysis of globally expressed differential genes in high-grade serous ovarian carcinoma cell lines. DEGs, HGSOC, miRNAs, PPI, TFs
95  2020 Cytoplasmic versus nuclear THR alpha expression determines survival of ovarian cancer patients. IHC, IR, OS, THR
96  2020 Elimination of dormant, autophagic ovarian cancer cells and xenografts through enhanced sensitivity to anaplastic lymphoma kinase inhibition. ALK, siRNA
97  2020 Ferroptosis of epithelial ovarian cancer: genetic determinants and therapeutic potential. ---
98  2020 Identification of four hub genes as promising biomarkers to evaluate the prognosis of ovarian cancer in silico. GEO, GO, KEGG, OS, PFS, PPI, WGCNA
99  2020 Identification of three molecular subtypes based on immune infiltration in ovarian cancer and its prognostic value. OS, TIICs
100  2020 IL-6 promotes nuclear translocation of HIF-1alpha to aggravate chemoresistance of ovarian cancer cells. IL-6, STAT3